Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin.
Fucoidan, poly(L-fucopyranose) linked primarily alpha 1----2 with either a C3- or a C4-sulfate, is an effective anticoagulant in vitro and in vivo (Springer, G. F., Wurzel, H. A., McNeal, G. M., Jr., Ansell, N. J., and Doughty, M. F. (1957) Proc. Soc. Exp. Biol. Med. 94, 404-409). We have determined the antithrombin effects of fucoidan on the glycosaminoglycan-binding plasma proteinase inhibitors antithrombin III and heparin cofactor II. Fucoidan enhances the heparin cofactor II-thrombin reaction more than 3500-fold. The apparent second-order rate constant of thrombin inhibition by heparin cofactor II increases from 4 x 10(4) (in the absence of fucoidan) to 1.5 x 10(8) M-1 min-1 as the fucoidan concentration increases from 0.1 to 10 micrograms/ml and then decreases as fucoidan is increased above 10 micrograms/ml. The fucoidan reaction with heparin cofactor II-thrombin is kinetically equivalent to a "template model." Apparent fucoidan-heparin cofactor II and fucoidan-thrombin dissociation constants are 370 and 1 nM, respectively. The enhancement of thrombin inhibition by fucoidan, like heparin and dermatan sulfate, is eliminated by selective chemical modification of lysyl residues either of heparin cofactor II or of thrombin. The fucoidan-antithrombin III reactions with thrombin and factor Xa are accelerated maximally 285- and 35-fold at fucoidan concentrations of 30 and 500 micrograms/ml, respectively. Using human plasma and 125I-labeled thrombin in an ex vivo system, the heparin cofactor II-thrombin complex is formed preferentially over the antithrombin III-thrombin complex in the presence of 10 micrograms/ml fucoidan. Our results indicate that heparin cofactor II is activated by fucoidan in vitro and in an ex vivo plasma system and suggest that the major antithrombin activity of fucoidan in vivo is mediated by heparin cofactor II and not by antithrombin III.
Church
F C
FC
Department of Pathology, University of North Carolina School of Medicine, Chapel Hill 27599.
Meade
J B
JB
Treanor
R E
RE
Whinna
H C
HC
D000990:Antithrombin III / Q000378:metabolism / Q000494:pharmacology*; D002118:Calcium / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D015951:Factor Xa; D006023:Glycoproteins / Q000378:metabolism / Q000494:pharmacology*; D006493:Heparin / Q000378:metabolism; D015844:Heparin Cofactor II; D006801:Humans; D007700:Kinetics; D011134:Polysaccharides / Q000378:metabolism / Q000494:pharmacology*; D015842:Serine Proteinase Inhibitors; D013050:Spectrometry, Fluorescence; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism
D006023:Glycoproteins; D011134:Polysaccharides; D015842:Serine Proteinase Inhibitors; D015844:Heparin Cofactor II; D000990:Antithrombin III; D006493:Heparin; C007789:fucoidan; D013917:Thrombin; D015951:Factor Xa; D002118:Calcium